HF Advisory Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.69M Buy
2,246
+278
+14% +$284K 0.83% 47
2026
Q1
$1.81M Sell
1,968
-57
-3% -$57.8K 0.62% 64
2025
Q4
$2.18M Sell
2,025
-198
-9% -$189K 0.76% 50
2025
Q3
$1.7M Buy
2,223
+586
+36% +$436K 0.62% 58
2025
Q2
$1.28M Buy
1,637
+192
+13% +$149K 0.5% 74
2025
Q1
$1.19M Buy
1,445
+224
+18% +$186K 0.52% 78
2024
Q4
$943K Sell
1,221
-1,088
-47% -$901K 0.43% 85
2024
Q3
$2.05M Sell
2,309
-48
-2% -$43.2K 0.95% 34
2024
Q2
$2.13M Sell
2,357
-202
-8% -$162K 1.1% 22
2024
Q1
$1.99M Sell
2,559
-41
-2% -$29.2K 1.11% 25
2023
Q4
$1.52M Sell
2,600
-563
-18% -$329K 0.97% 36
2023
Q3
$1.7M Sell
3,163
-466
-13% -$240K 1.26% 18
2023
Q2
$1.7M Buy
3,629
+170
+5% +$71.3K 1.34% 17
2023
Q1
$1.19M Buy
3,459
+605
+21% +$204K 1.05% 28
2022
Q4
$1.04M Buy
+2,854
New +$1.01M 1.06% 25

Other funds holding LLY

HF Advisory Group's LLY Position: Q2 2026 in Review

HF Advisory Group increased its Eli Lilly (LLY) stake by 14% in Q2 2026, buying an estimated $284K and bringing the position to 2,246 shares worth $2.69M. The position accounts for 0.83% of the portfolio, ranked #47.

HF Advisory Group first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. 893 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • HF Advisory Group held 2,246 shares of Eli Lilly worth $2.69M as of Q2 2026.
  • HF Advisory Group bought 278 Eli Lilly shares in Q2 2026, an estimated $284K.
  • Eli Lilly made up 0.83% of HF Advisory Group's portfolio in Q2 2026, its #47 holding.
  • HF Advisory Group first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • 893 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on HF Advisory Group's 13F filing for Q2 2026, filed 9 Jul 2026.